TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9379380

Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5%
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 144

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 144
Study: 8471327

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant combination chemotherapy (AMF); 5‐fluorouracil 500 mg/m2, doxorubicin 40 mg/m2, mitomycin C 6 mg/m2 (n = 30) once every 3 weeks for six cycles
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy) (n = 31)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant combination chemotherapy (AMF)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 61
Study: 3898908

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (80 micrograms in the epidural test dose of bupivacaine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous fentanyl (infusion designed to produce comparable plasma concentrations)
Number of subjects: 20
Study: 30413866

Group type: EXPERIMENTAL
Intervention: Follow-up postoperative call (FPC) policy, implemented within 48 to 72 hours of discharge
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control group (no follow-up call)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Follow-up postoperative call (FPC) policy
Number of subjects: 459
Study: 28594249

Group type: EXPERIMENTAL
Intervention: School nurse-administered inhaled corticosteroids (ICS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (home-administered ICS)
Number of subjects: 46
Study: 26149243

Group type: EXPERIMENTAL
Intervention: Weight loss intervention program
Number of subjects: 0
Study: 25891550

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (IM IFNβ‐1a) 30 μg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 22857881

Group type: EXPERIMENTAL
Intervention: Nutritional support with whey peptide and low-intensity exercise therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no nutritional support)
Number of subjects: 36
Study: 20300048

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Other antihypertensive drug monotherapies
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 18400141

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg kg(‐1) in 10 mL normal saline)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fentanyl (1 microg kg(‐1) in 10 mL normal saline)
Number of subjects: 52
Study: 16088821

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of nevirapine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of lamivudine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of zidovudine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nevirapine in infants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lamivudine in infants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zidovudine in infants
Number of subjects: 20
Study: 11985532

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) or Mycophenolate mofetil (MMF) after conversion from Cyclosporin A (CsA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose immunosuppression (after tapering)
Number of subjects: 0
Study: 10884453

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units)
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 1292
Study: 9307633

Group type: EXPERIMENTAL
Intervention: 0.3% carbomer gel
Number of subjects: 123

Group type: COMPARATOR
Intervention: placebo (mannitol solution with benzalkonium chloride 0.008%)
Number of subjects: 123

Group type: COMPARATOR
Intervention: carbomer gel and placebo
Number of subjects: 123
Study: 8320576

Group type: EXPERIMENTAL
Intervention: Long program (2 1/2‐day course)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Short program (4 1/2‐hour workshop)
Number of subjects: 53
Study: 3330183

Group type: EXPERIMENTAL
Intervention: Vitamin B6 treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31562660

Group type: EXPERIMENTAL
Intervention: Caring letters (CL) intervention - 13 caring e‐mails over two years
Number of subjects: 1318

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: Caring letters (CL) intervention
Number of subjects: 1318
Study: 30430649

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6 × 10^9 cfu)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bifidobacterium lactis HN019 (9 × 10^9 cfu)
Number of subjects: 0
Study: 27309886

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (240 mg in 125 mL saline solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (125 mL saline solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (lidocaine and control)
Number of subjects: 0
Study: 24360787

Group type: EXPERIMENTAL
Intervention: Epirubicin and cyclophosphamide then paclitaxel
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Paclitaxel with or without gemcitabine followed by epirubicin and cyclophosphamide
Number of subjects: 831

Group type: COMPARATOR
Intervention: Epirubicin and cyclophosphamide first
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Paclitaxel and gemcitabine then epirubicin and cyclophosphamide
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 831
Study: 22759250

Group type: EXPERIMENTAL
Intervention: HA-1 (Belotero Basic/Balance)
Number of subjects: 20

Group type: COMPARATOR
Intervention: HA-2 (Restylane)
Number of subjects: 20

Group type: COMPARATOR
Intervention: HA-3 (Juvéderm Ultra 3/Juvéderm Ultra Plus XC)
Number of subjects: 20
Study: 20067650

Group type: EXPERIMENTAL
Intervention: Embolisation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Endoscopic resection without embolisation
Number of subjects: 23
Study: 18068284

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychosocial treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatments (Methylphenidate + Psychosocial treatments)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments (Methylphenidate, Psychosocial treatments, Combined treatments)
Number of subjects: 0
Study: 15528979

Group type: EXPERIMENTAL
Intervention: Single doses of GW572016
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Multiple doses of GW572016 (25 mg, 100 mg, 175 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 12629229

Group type: EXPERIMENTAL
Intervention: alpha‐[11C] methyl‐L‐tryptophan (alpha‐MTrp) PET
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2‐[18F]‐fluoro‐deoxy‐glucose (FDG) PET
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 14

Group type: COMPARATOR
Intervention: alpha‐MTrp PET
Number of subjects: 14
Study: 10562777

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia at 1.2 MAC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia at 1.2 MAC
Number of subjects: 14

Group type: COMPARATOR
Intervention: Awake state
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All conditions (awake and anaesthetized)
Number of subjects: 14
Study: 8561642

Group type: EXPERIMENTAL
Intervention: Heparin-coated oxygenator
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bubble oxygenator
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hollow-fiber oxygenator
Number of subjects: 60
Study: 1888786

Group type: EXPERIMENTAL
Intervention: 40% oxygen via a venturi mask during transport
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room air (control group)
Number of subjects: 0
Study: 31580552

Group type: EXPERIMENTAL
Intervention: Water pipe smoking (WP)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 500
Study: 27886013

Group type: EXPERIMENTAL
Intervention: Individualized music intervention
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Multisensory stimulation environment (MSSE)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison between individualized music and MSSE
Number of subjects: 22

Group type: COMPARATOR
Intervention: Correlation with agitation, anxiety, cognitive function, and dementia severity
Number of subjects: 22
Study: 25871602

Group type: EXPERIMENTAL
Intervention: Teleconference-delivered fatigue management program
Number of subjects: 81
Study: 24060179

Group type: EXPERIMENTAL
Intervention: p16 positivity
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: EGFR expression (low)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: EGFR expression
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Combination of EGFR/p16
Number of subjects: 336
Study: 21263371

Group type: EXPERIMENTAL
Intervention: Cefazolin (two doses during removal of the catheter)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No antimicrobial agent (control group)
Number of subjects: 88
Study: 19208352

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet (<50 g/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (HC) diet (>180 g/day)
Number of subjects: 22
Study: 18667140

Group type: EXPERIMENTAL
Intervention: Various nonpharmacologic interventions and therapies tried by patients, including assessment of success rates and patient function.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Establishment of a secure physician-patient relationship and open communication.
Number of subjects: 0
Study: 15363824

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (20 nonpharmacologic, 36 beta‐blockers, 33 angiotensin receptor blocker)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment after 12 months
Number of subjects: 89
Study: 11181662

Group type: EXPERIMENTAL
Intervention: IV carboplatin (area under curve 9) every 28 days for two courses, then IV paclitaxel 135 mg/m(2) over 24 hours followed by intraperitoneal (IP) cisplatin 100 mg/m(2) every 3 weeks for six courses
Number of subjects: 462

Group type: COMPARATOR
Intervention: IV cisplatin 75 mg/m(2) every 3 weeks for six courses plus IV paclitaxel 135 mg/m(2) over 24 hours
Number of subjects: 462
Study: 9692280

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Qualitative studies or surveys
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Longitudinal design studies
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Organization and administration issues studies
Number of subjects: 1063
Study: 8080345

Group type: EXPERIMENTAL
Intervention: Tryptophan-deficient amino acid mixture
Number of subjects: 39

Group type: COMPARATOR
Intervention: Balanced amino acid mixture (placebo)
Number of subjects: 39
Study: 2510287

Group type: EXPERIMENTAL
Intervention: Rioprostil 150 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11960

Group type: EXPERIMENTAL
Intervention: 4 mg lorazepam
Number of subjects: 21

Group type: COMPARATOR
Intervention: 20 mg papaveretum/400 mug hyoscine
Number of subjects: 21
Study: 31722646

Group type: EXPERIMENTAL
Intervention: Individuals with serious mental disorders
Number of subjects: 50551

Group type: COMPARATOR
Intervention: Control group (matched participants)
Number of subjects: 50551
Study: 30999270

Group type: EXPERIMENTAL
Intervention: Gluteus medius (GMED) activity in CAI group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy counterparts (control group)
Number of subjects: 20
Study: 28185260

Group type: EXPERIMENTAL
Intervention: 4 mg/kg sugammadex (Group S)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.35 mg/kg neostigmine and 0.02 mg/kg atropine (Group N)
Number of subjects: 60
Study: 26378650

Group type: EXPERIMENTAL
Intervention: Culturally tailored, computer-delivered media-based intervention
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo comparison condition
Number of subjects: 216
Study: 23380907

Group type: EXPERIMENTAL
Intervention: Laser acupuncture as adjunct to reversible occlusal splint therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo laser associated with occlusal splint therapy
Number of subjects: 40
Study: 21872490

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 88

Group type: COMPARATOR
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 88
Study: 18362871

Group type: EXPERIMENTAL
Intervention: CBZ-ERC
Number of subjects: 155
Study: 16533101

Group type: EXPERIMENTAL
Intervention: Survey on perceived severity of childhood obesity
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Support for interventions such as regulation of restaurant portions and fast food advertising
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Logistic regressions examining differences in obesity attitudes
Number of subjects: 1047
Study: 14557420

Group type: EXPERIMENTAL
Intervention: T4 plus T3
Number of subjects: 40

Group type: COMPARATOR
Intervention: T4 plus placebo
Number of subjects: 40
Study: 11202586

Group type: EXPERIMENTAL
Intervention: NHS breast screening programme (NHSBSP)
Number of subjects: 0
Study: 10176125

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (NP)
Number of subjects: 70
Study: 1490543

Group type: EXPERIMENTAL
Intervention: Invitation letter containing an appointment
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Invitation letter with high satisfaction ratings
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Health check intervention
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Overall response to health checks
Number of subjects: 872
Study: 4037555

Group type: EXPERIMENTAL
Intervention: Weekly pulse methotrexate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28887640

Group type: EXPERIMENTAL
Intervention: G10 group received two IV doses of 10 mg/kg of TXA
Number of subjects: 80

Group type: COMPARATOR
Intervention: G20 group received two doses of 20 mg/kg of TXA
Number of subjects: 80
Study: 27275858

Group type: EXPERIMENTAL
Intervention: Descriptive and informative method (Group A)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Learning method based on problems (Group B)
Number of subjects: 312
Study: 25263395

Group type: EXPERIMENTAL
Intervention: Red wine (12% ethanol, 1758 mg/L total polyphenols) for 4 weeks
Number of subjects: 34
Study: 23051744

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 7.5 g divided into three daily doses
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: KRG and placebo
Number of subjects: 28
Study: 20801749

Group type: EXPERIMENTAL
Intervention: Brief educational intervention and periodic follow‐up contacts (BIC)
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 1867
Study: 19759838

Group type: EXPERIMENTAL
Intervention: Real TMS (20 minutes, 10 Hz, 10 seconds-ON, 20 seconds-OFF for a total of 4000 pulses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Real TMS
Number of subjects: 20
Study: 15715969

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 100 mg, single dose
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 200 mg, single dose
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 400 mg, single dose
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 27
Study: 14609883

Group type: EXPERIMENTAL
Intervention: Olanzapine, 5 to 20 mg/d
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Olanzapine-fluoxetine combination, 6 and 25, 6 and 50, or 12 and 50 mg/d
Number of subjects: 833

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 833

Group type: COMPARATOR
Intervention: Olanzapine vs Placebo
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Olanzapine-fluoxetine vs Olanzapine
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Treatment-emergent mania
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Adverse events for olanzapine-fluoxetine
Number of subjects: 833
Study: 10805798

Group type: EXPERIMENTAL
Intervention: HAART (highly active antiretroviral therapy)
Number of subjects: 73
Study: 8825804

Group type: EXPERIMENTAL
Intervention: Preprepared solid foods (including egg yolk) in addition to breast milk starting at 4 months (n = 91)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Exclusively breast-fed (EBF) infants (n = 50)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 20 infants with the highest protein intakes (solid foods) matched to 20 EBF infants
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: 20 infants with the lowest protein intakes (EBF) matched to 20 infants given solid foods
Number of subjects: 141
Study: 1375598

Group type: EXPERIMENTAL
Intervention: Synthetic porcine galanin (0.5 mg in 100 mL saline)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline infusion (100 mL saline)
Number of subjects: 13
Study: 3893700

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine cream 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% Clotrimazole cream
Number of subjects: 0
Study: 31142044

Group type: EXPERIMENTAL
Intervention: 10 mg-Zn/day
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 5 mg-Zn/day
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 28991918

Group type: EXPERIMENTAL
Intervention: Rapid test-and-treat strategy plus Lactobacillus reuteri DSM 17938
Number of subjects: 76

Group type: COMPARATOR
Intervention: No stool testing and placebo treatment
Number of subjects: 76
Study: 25620670

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin (FC) measurement
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Step-up treatment after endoscopic recurrence
Number of subjects: 135

Group type: COMPARATOR
Intervention: Endoscopic analysis (Rutgeerts score)
Number of subjects: 135
Study: 23521325

Group type: EXPERIMENTAL
Intervention: Avanafil 100 mg
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Avanafil 100/200 mg
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Number of subjects: 686
Study: 21802314

Group type: EXPERIMENTAL
Intervention: Tris-acryl microspheres
Number of subjects: 56

Group type: COMPARATOR
Intervention: PVA microspheres
Number of subjects: 56
Study: 19221810

Group type: EXPERIMENTAL
Intervention: Invasive cantilever RBFPD
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Minimal invasive cantilever RBFPD
Number of subjects: 42

Group type: COMPARATOR
Intervention: Two-retainer RBFPD (control)
Number of subjects: 42
Study: 16443885

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: glyburide
Number of subjects: 145
Study: 15262624

Group type: EXPERIMENTAL
Intervention: Vision during acquisition phase
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: No vision after 560 trials of practice
Number of subjects: 20
Study: 11773989

Group type: EXPERIMENTAL
Intervention: Eprosartan 300 mg twice daily
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 9924262

Group type: EXPERIMENTAL
Intervention: Lower-carbohydrate test meal (0.5 g fat/kg body weight + 17 g carbohydrate as lactose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher-carbohydrate test meal (0.5 g fat/kg body weight + 136 g carbohydrate, 60 g sucrose)
Number of subjects: 0
Study: 7995896

Group type: EXPERIMENTAL
Intervention: Lang stereotest
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Lang stereotest combined with Snellen acuity
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Lang stereotest combined with refractive error
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Lang stereotest (subgroup of 17 multiply handicapped children)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Lang stereotest (test/retest reliability subgroup of 27 children)
Number of subjects: 183
Study: 3354490

Group type: EXPERIMENTAL
Intervention: Low-fat diet (25% of calories)
Number of subjects: 6

Group type: COMPARATOR
Intervention: High-fat diet (46% of calories)
Number of subjects: 6
Study: 29652551

Group type: EXPERIMENTAL
Intervention: 3000 mg of fish-derived n-3 eicosapentaenoic and docosahexaenoic acids
Number of subjects: 349

Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 349
Study: 28912192

Group type: EXPERIMENTAL
Intervention: Mechanical cervical ripening with Cervical Ripening Balloon (Cook-Medical Europe, Ireland) for 24 hours
Number of subjects: 1220

Group type: COMPARATOR
Intervention: Pharmacological cervical ripening with Propess system (10 mg of dinoprostone, Ferring SAS, France) before oxytocin administration
Number of subjects: 1220
Study: 26571898

Group type: EXPERIMENTAL
Intervention: Acupuncture at left Hegu (LI 4)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acupuncture at right Hegu (LI 4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison between left‐acupoint group and right‐acupoint group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acupuncture feelings and MGH acupuncture sensation scale (MASS)
Number of subjects: 80
Study: 23277105

Group type: EXPERIMENTAL
Intervention: Pneumatic dilation (PD)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Laparoscopic Heller myotomy (LHM)
Number of subjects: 176
Study: 21443600

Group type: EXPERIMENTAL
Intervention: Alitretinoin 40 mg after fasting (treatment A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alitretinoin 40 mg after a standard breakfast (treatment B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alitretinoin with food
Number of subjects: 30
Study: 19563951

Group type: EXPERIMENTAL
Intervention: Azithromycin 600 mg once daily for 3 days and then 600 mg once weekly for 15 weeks
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Combination of statins and acetylsalicylic acid (ASA)
Number of subjects: 247